Article citationsMore>>

A. Puel, R. Doffinger, A. Natividad, M. Chrabieh, G. Barcenas-Morales, C. Picard, et al., “Autoantibodies against IL-17A, IL-17F, and IL-22 in Patients with Chronic Mucocutaneous Candidiasis and Autoimmune Polyendocrine Syndrome Type I,” Journal of Experimental Medicine, Vol. 207, No. 2, 2010, pp. 291-297. doi:10.1084/jem.20091983?

has been cited by the following article:

• TITLE: Unmet Needs in the Treatment of Rheumatoid Arthritis

  AUTHORS: Janet Pope, Bernard Combe

  KEYWORDS: Rheumatoid Arthritis; Biologics; Tumor Necrosis Factor Inhibitors; Unmet Need; Interleukin-17A; IL-17 Inhibitors; Treatment Challenges

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.3 No.2, May 16, 2013

  ABSTRACT: Biologics have greatly improved the management of rheumatoid arthritis (RA), demonstrating efficacy and safety in alleviating symptoms, inhibiting bone erosion, and preventing loss of function. Unmet therapeutic needs in RA remain; however, further advances require an understanding of issues left unaddressed under the current treatment paradigm. Most biologic-na?ve and biologic-pretreated patients who initiate a biologic therapy, for example, do not reach American College of Rheumatology 50% (ACR50) response, and few achieve remission. Responses are often not durable, prompting frequent treatment switching. Predictive markers are unavailable to guide therapy selection, and clinical trial data are lacking on whether a tumor necrosis factor inhibitor (TNFi) is the best first-line biologic and on the optimal sequence of use for the different biologics. Risk of serious infection is the major safety concern. Translating preclinical and clinical findings into new therapeutics may help address unmet needs. An increasing body of evidence indicates that the cytokine interleukin (IL)-17A represents an important therapeutic target; ongoing trials with IL-17A inhibitors will determine whether these agents can address some of the unmet needs associated with current biologics.